Illumina, Inc. (ILMN)
NASDAQ: ILMN · Real-Time Price · USD
99.97
+2.74 (2.82%)
At close: Oct 23, 2025, 4:00 PM EDT
99.00
-0.97 (-0.97%)
After-hours: Oct 23, 2025, 7:12 PM EDT
Illumina Revenue
Illumina had revenue of $1.06B in the quarter ending June 29, 2025, a decrease of -4.77%. This brings the company's revenue in the last twelve months to $4.28B, down -3.27% year-over-year. In the year 2024, Illumina had annual revenue of $4.37B, down -2.93%.
Revenue (ttm)
$4.28B
Revenue Growth
-3.27%
P/S Ratio
3.70
Revenue / Employee
$413,115
Employees
10,370
Market Cap
15.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 29, 2024 | 4.37B | -132.00M | -2.93% |
| Dec 31, 2023 | 4.50B | -80.00M | -1.75% |
| Jan 1, 2023 | 4.58B | 58.00M | 1.28% |
| Jan 2, 2022 | 4.53B | 1.29B | 39.73% |
| Jan 3, 2021 | 3.24B | -304.00M | -8.58% |
| Dec 29, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 30, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 1, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Jan 3, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 422.82B |
| Johnson & Johnson | 92.15B |
| Merck & Co. | 63.62B |
| AbbVie | 58.33B |
| AstraZeneca | 56.50B |
| Novartis AG | 55.19B |
| Eli Lilly and Company | 53.26B |
| Novo Nordisk | 49.11B |
ILMN News
- 2 days ago - Illumina: Innovation Outweighs Short-Term Risks - A Long-Term Buy Ahead Of Q3 Earnings - Seeking Alpha
- 8 days ago - Illumina fuels multiomic discovery with launch of 5-base solution, unlocking simultaneous genomic and epigenomic insights - PRNewsWire
- 8 days ago - Illumina constellation mapped read technology uncovers hard-to-see genomic insights in GeneDx pilot - PRNewsWire
- 9 days ago - Illumina to Announce Third Quarter 2025 Financial Results on Thursday, October 30, 2025 - PRNewsWire
- 22 days ago - Illumina launches new business to accelerate technology and data-driven discovery - PRNewsWire
- 27 days ago - ILMN Stock vs. IQV Stock - Forbes
- 4 weeks ago - Illumina advances personalized cancer care with new pharma development partnerships - PRNewsWire
- 5 weeks ago - Alnylam Pharmaceuticals joins Alliance for Genomic Discovery, expanding diverse clinical genomic dataset to drive precision medicine - PRNewsWire